期刊文献+

骨髓增殖性肿瘤的治疗进展 被引量:2

Advances in the treatment of myeloproliferative neoplasms
原文传递
导出
摘要 骨髓增殖性肿瘤(myeloproliferative neoplasms,MPN)系一组克隆性造血干细胞疾病,其特征为髓系(粒、红、巨核或肥大)细胞一系或多系增殖,临床表现为外周血一种或多种血细胞增多,常伴有肝、脾肿大、出血倾向、血栓形成及髓外造血。经典的BCR/ABL1阴性的MPN包括真性红细胞增多症(polycythemia vera,PV)、原发性血小板增多症(essential thrombocythemia,ET)及骨髓纤维化(myelofibrosis,MF)。
作者 韩冰 王璐
出处 《临床血液学杂志》 CAS 2015年第6期926-929,932,共5页 Journal of Clinical Hematology
关键词 骨髓增殖性肿瘤 治疗 myeloproliferative neoplasms treatment
  • 相关文献

参考文献32

  • 1Masa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelo- fibrosis (post-PV MF), post essential thrombocythe- mia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP) :Consensus on terminology by the interna-tional working group for myelofibrosis research and treatment (IWG-MRT) [J]. Leuk Res, 2007, al: 737--740.
  • 2Tefferi A,Thiele J, Orazi A, et al. Proposals and rati- onale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis~ recom- mendations from an ad hoc international expert panel [J]. Blood, 2007,110 : 1092-- 1097.
  • 3Scott LM. The JAK2 exon 12 mutations: a compre- hensive review[J].Am J Hematol, 2011, 86 : 668-676.
  • 4Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk- stratification and management [J]. Am J Hematol, 2015,90:162--173.
  • 5Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with poly- cythemia vera[J]. J Clin Oncol, 2005,23:2224- 2232.
  • 6Barbul T, Barosl G, Birgegard G, et al. Philadelphia- negative classical myeloproliferative neoplasms, criti- cal concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011,29 : 761-770.
  • 7Barbui T, Finazzi MC, Finazzi G, et al. Front-line ther- apy in polycythemia vera and essential throbocythe- mia[J ]. Blood, 2012,26 : 205-211.
  • 8Silver RT. Recombinant interferon-alpha for treat- ment of polycythaemia vera [J]. Lacent, 1988, 332 : 403--413.
  • 9Griesshammer M,Olisslinger H,Mesa R. Current and future treatment options for polycythemia vera[J]. Ann Hematol,2015,94 : 901-910.
  • 10Passamonti F, Rumi E, Della Porta MG, et al. IN- CB018424,a selective inhibitor of JAK1 and JAK2, downregulates the expression of leukocyte alkaline phosphatase (LAP) on circulating granulocytes in pa- tients with polycythemia vera and essential thrombo- cythemiaI-abstract]. Blood ( ASH Annual Meeting Abstracts), 2009,114 : 2905.

同被引文献10

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部